EPSTEIN-BARR VIRUS-INDUCED DISEASES IN IMMUNE DEFICIENT PATIENTS

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

EPSTEIN-BARR VIRUS-INDUCED DISEASES IN IMMUNE DEFICIENT PATIENTS

UCLA Symp Mol Cell Biol; New Ser 21:253-72 1984. Unique Identifier : AIDSLINE ICDB/86622808
Purtilo DT; Harada S; Meuwissen H; Lipscomb H; Ochs H; Sonnabend J; Manolov G; Manolova Y; Depts. of Pathology and Lab. Medicine, Univ. of Nebraska Medical; Center, 42nd and Dewey Avenue, Omaha, NE 68105

Abstract: Epstein-Barr virus (EBV)-induced disease is reviewed with respect to selected studies performed on patients with immune deficiency, salient clinical and pathological features of some of the diseases, and methods for documenting infection by Epstein-Barr virus (EBV) (serology, cell-mediated immune studies, detection of EB nuclear-associated antigen (EBNA), and hybridization for genome). Anti-viral capsid antigen, anti-early antigen, and anti-EBNA levels were determined in patients with the various primary immune deficiency syndromes. Major differences in antibody reactivity against EBV-specific antigens were seen. Low anti-EBNA titers occurred in patients with X-linked lymphoproliferative syndrome, X-linked agammaglobulinemia, ataxia telangiectasia, and Wiskott-Aldrich syndrome. Patients with common variable immune deficiency tended to have relative normal anti-EBNA and reactivation of the virus. Renal transplant recipients and a subset of highly promiscuous male homosexuals have developed fatal EBV-associated lesions. It is proposed that the conversion of EBV-initiated polyclonal B cell proliferation to monoclonal malignancy occurs as a result of molecular or cytogenetic rearrangements of immunoglobulin genes and c-myc oncogene. Improvement of immune responses to the virus in renal transplant patients by withdrawal of immunosuppressive therapy has been associated with regression of polyclonal or monoclonal lesions. The development of immunosuppressive drugs specifically preventing rejection of grafts, antiviral agents, and detection of infection in early stages may obviate these life-threatening diseases in the future. (31 Refs)

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Adolescence Adult Antibodies, Viral/ANALYSIS Antigens, Viral/IMMUNOLOGY Burkitt's Lymphoma/IMMUNOLOGY Child Genes, Viral Herpesvirus 4, Human/GENETICS/IMMUNOLOGY Human Immunity, Cellular Immunologic Deficiency Syndromes/*IMMUNOLOGY Infectious Mononucleosis/*IMMUNOLOGY Kidney/TRANSPLANTATION Kidney Transplantation Lymphoproliferative Disorders/IMMUNOLOGY Male Tumor Virus Infections/*IMMUNOLOGY Virus Activation Wiskott-Aldrich Syndrome/IMMUNOLOGY MEETING PAPER

860530
M8650244

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .